Starting Clinical Trial for PTEN and P1K3C defects in Prostrate Cancer tumors

In 4th year since metastasized PCa initially diagnosed. This is my 3rd Clinical Trial, NCT01884285, Phase 1 evaluation of AZD8186. My first clinical trial was with Galeterone, dropped after 31 days due to Uticaria reaction. 2nd trial was on Enzalutimide, which went for 33 cycles (4 week cycles) and a follow-up solid tumor biopsy. Stopped Enzalutimide due to extreme fatigue. Biopsy genomic analysis showed PTEN, ATM, P1K3C*, and other related defects. The AZD drug is being used on other cancers, too. (Squamous Non-Small Cell Lung Cancer (sqNSCLC);

Triple Negative Breast Cancer (TNBC). These genomic areas are the ones that control cancer cell life and death pathways. You can see more of my history by checking my other inputs.

1 Reply

  • Cool! As of a few years ago, there were no trials that targeted PTEN. Times change.